Osteoprotegerin (OPG) is a recently cloned member of the tumour necrosis factor receptor family. It has been suggested that this secreted glycoprotein acts as an inhibitor of osteoclastic differentiation. Expression of OPG has previously been demonstrated in a number of tissues. However, it is still unclear whether or not OPG is expressed by human osteoblasts. We have used the RNase protection assay to demonstrate the OPG transcript in primary cultured human osteoblast-like cells, human marrow stroma cells and osteosarcoma cell lines. Furthermore, we have studied the effect of glucocorticoids on OPG mRNA levels in these cells. We demonstrate that glucocorticoids decrease the OPG transcript in a dose- and time-dependent manner. The time-course study reveals that hydrocortisone (10(-6) M) decreases OPG mRNA levels within 2 h. This decrease is transient, reaching control levels again after 24 h. Our findings demonstrate that human osteoblasts express the mRNA corresponding to OPG, an inhibitor of osteoclast differentiation. The finding that OPG mRNA levels are decreased by glucocorticoids indicates that a reduced production of OPG from osteoblasts and/or marrow stroma cells could, in part, explain glucocorticoid-induced bone resorption.

This article has been cited by other articles:

				A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]

				C. Swanson, M. Lorentzon, H. H. Conaway, and U. H. Lerner Glucocorticoid Regulation of Osteoclast Differentiation and Expression of Receptor Activator of Nuclear Factor-{kappa}B (NF-{kappa}B) Ligand, Osteoprotegerin, and Receptor Activator of NF-{kappa}B in Mouse Calvarial Bones Endocrinology, July 1, 2006; 147(7): 3613 - 3622. [Abstract] [Full Text] [PDF]

				E. GARCIA-VALDECASAS-CAMPELO, E. GONZALEZ-REIMERS, F. SANTOLARIA-FERNANDEZ, M. J. DE LA VEGA-PRIETO, A. MILENA-ABRIL, M. J. SANCHEZ-PEREZ, A. MARTINEZ-RIERA, and M. D. L. A. GOMEZ-RODRIGUEZ SERUM OSTEOPROTEGERIN AND RANKL LEVELS IN CHRONIC ALCOHOLIC LIVER DISEASE Alcohol Alcohol., May 1, 2006; 41(3): 261 - 266. [Abstract] [Full Text] [PDF]

				A. Rogers and R. Eastell Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor {kappa}B Ligand: Clinical Utility in Metabolic Bone Disease Assessment J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6323 - 6331. [Abstract] [Full Text] [PDF]

				O Di Munno, M Mazzantini, A D. Sedie, M Mosca, and S Bombardieri Risk factors for osteoporosis in female patients with systemic lupus erythematosus Lupus, September 1, 2004; 13(9): 724 - 730. [Abstract] [PDF]

				E. C. Buxton, W. Yao, and N. E. Lane Changes in Serum Receptor Activator of Nuclear Factor-{kappa}B Ligand, Osteoprotegerin, and Interleukin-6 Levels in Patients with Glucocorticoid-Induced Osteoporosis Treated with Human Parathyroid Hormone (1-34) J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3332 - 3336. [Abstract] [Full Text] [PDF]

				C A Pineau, M B Urowitz, P J Fortin, D Ibanez, and D D Gladman Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density Lupus, June 1, 2004; 13(6): 436 - 441. [Abstract] [PDF]

				J. E. Onyia, R. J. S. Galvin, Y. L. Ma, D. L. Halladay, R. R. Miles, X. Yang, T. Fuson, R. L. Cain, Q. Q. Zeng, S. Chandrasekhar, et al. Novel and Selective Small Molecule Stimulators of Osteoprotegerin Expression Inhibit Bone Resorption J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 369 - 379. [Abstract] [Full Text]

				A. Takuma, T. Kaneda, T. Sato, S. Ninomiya, M. Kumegawa, and Y. Hakeda Dexamethasone Enhances Osteoclast Formation Synergistically with Transforming Growth Factor-{beta} by Stimulating the Priming of Osteoclast Progenitors for Differentiation into Osteoclasts J. Biol. Chem., November 7, 2003; 278(45): 44667 - 44674. [Abstract] [Full Text] [PDF]

				D H. Jones, Y-Y Kong, and J M Penninger Role of RANKL and RANK in bone loss and arthritis Ann Rheum Dis, November 1, 2002; 61(90002): ii32 - 39. [Abstract] [Full Text] [PDF]

				A. Lipton, S. M. Ali, K. Leitzel, V. Chinchilli, L. Witters, L. Engle, D. Holloway, P. Bekker, and C. R. Dunstan Serum Osteoprotegerin Levels in Healthy Controls and Cancer Patients Clin. Cancer Res., July 1, 2002; 8(7): 2306 - 2310. [Abstract] [Full Text] [PDF]

				M. Schoppet, K. T. Preissner, and L. C. Hofbauer RANK Ligand and Osteoprotegerin: Paracrine Regulators of Bone Metabolism and Vascular Function Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 549 - 553. [Abstract] [Full Text] [PDF]

				T. Yamagishi, E. Otsuka, and H. Hagiwara Reciprocal Control of Expression of mRNAs for Osteoclast Differentiation Factor and OPG in Osteogenic Stromal Cells by Genistein: Evidence for the Involvement of Topoisomerase II in Osteoclastogenesis Endocrinology, August 1, 2001; 142(8): 3632 - 3637. [Abstract] [Full Text] [PDF]

				N. Sasaki, E. Kusano, Y. Ando, K. Yano, E. Tsuda, and Y. Asano Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis Nephrol. Dial. Transplant., March 1, 2001; 16(3): 479 - 482. [Abstract] [Full Text] [PDF]

				D. L. Lacey, H. L. Tan, J. Lu, S. Kaufman, G. Van, W. Qiu, A. Rattan, S. Scully, F. Fletcher, T. Juan, et al. Osteoprotegerin Ligand Modulates Murine Osteoclast Survival in Vitro and in Vivo Am. J. Pathol., August 1, 2000; 157(2): 435 - 448. [Abstract] [Full Text] [PDF]

				L. C. Hofbauer and A. E. Heufelder The Role of Receptor Activator of Nuclear Factor-{kappa}B Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2355 - 2363. [Full Text]

				I Itonaga, A Sabokbar, D W Murray, and N A Athanasou Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages Ann Rheum Dis, January 1, 2000; 59(1): 26 - 31. [Abstract] [Full Text]

				L. C. Hofbauer, F. Gori, B. L. Riggs, D. L. Lacey, C. R. Dunstan, T. C. Spelsberg, and S. Khosla Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis Endocrinology, October 1, 1999; 140(10): 4382 - 4389. [Abstract] [Full Text]

				M. Schoppet, K. T. Preissner, and L. C. Hofbauer RANK Ligand and Osteoprotegerin: Paracrine Regulators of Bone Metabolism and Vascular Function Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 549 - 553. [Abstract] [Full Text] [PDF]